Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Ascendiant Capital starts IGC Pharma coverage with buy, sets $2.75 target on stock

Published Feb 12, 2024 09:10AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters.
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio

On Monday, Ascendiant Capital initiated coverage on IGC Pharma Inc. (NASDAQ:IGC), issuing a Buy rating and establishing a price target of $2.75 for the company's shares. The firm's coverage begins with a positive outlook on the pharmaceutical company's potential in addressing Alzheimer's disease, a condition currently lacking effective treatment options.

Alzheimer's disease stands out as one of the ten most fatal diseases in the United States without a known cure, the ability to slow its progression, or preventative measures. Existing medications offer only limited and temporary cognitive benefits for those afflicted. Ascendiant Capital's report highlights the urgent need for more effective treatments against this backdrop.

The analyst's commentary draws attention to the significant impact of Alzheimer's within the U.S., where an estimated 6.2 million individuals are living with the disease. This figure is anticipated to more than double, reaching 13 million by the year 2050. The financial ramifications are equally staggering, with the cost of care for Alzheimer's and other dementias expected to soar from approximately $305 billion in 2020 to an estimated $1.1 trillion annually by 2050.

Ascendiant Capital's decision to initiate coverage on IGC Pharma with a Buy rating suggests confidence in the company's potential to make inroads in the Alzheimer's treatment market. The firm's analysis indicates a belief in the value proposition of IGC Pharma's approach to a disease that poses a growing challenge to public health and the economy.

The introduction of IGC Pharma into Ascendiant Capital's coverage with a favorable outlook provides a glimpse into the potential advancements and financial implications in the biopharmaceutical sector, particularly concerning the treatment of Alzheimer's disease.

InvestingPro Insights

As Ascendiant Capital initiates coverage of IGC Pharma Inc. (NASDAQ:IGC) with a Buy rating, investors may find additional context in the real-time data and InvestingPro Tips for a deeper understanding of the company's financial health and market performance. IGC Pharma's focus on Alzheimer's treatment positions it in a critical area of unmet medical need, with the potential for significant impact on public health and the economy.

InvestingPro Data for IGC Pharma indicates a market capitalization of $19.44 million USD, reflecting the company's size in the pharmaceutical market. The company's P/E ratio stands at -1.8 (adjusted for the last twelve months as of Q2 2024), highlighting its current lack of profitability. However, revenue growth has been impressive, with a 98.08% increase over the last twelve months as of Q2 2024, suggesting a strong upward trend in sales.

Among the InvestingPro Tips, it's noteworthy that IGC Pharma holds more cash than debt on its balance sheet, which could provide financial stability and support for its research and development efforts. On the other hand, the company is quickly burning through cash, which investors should consider in the context of its growth strategy and future funding needs. The stock has experienced a significant return over the last week with a 10.11% price total return, indicating recent positive investor sentiment.

For those looking to delve deeper into IGC Pharma's prospects, additional InvestingPro Tips can be found on the platform, including insights on stock price volatility, liquidity, and the company's dividend policy. There are 7 additional InvestingPro Tips available, providing a comprehensive analysis for informed investment decisions. For access to these insights, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Ascendiant Capital starts IGC Pharma coverage with buy, sets $2.75 target on stock

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your profile, will be public on and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email